distearyplatin

Distearyplatin is a difattyacid platinum compound chemically engineered for improved delivery as part of nanoemulsion (NE) formulations in cancer therapy. It belongs to a family of lipid-modified platinum drugs designed to encapsulate in the oil core of NEs, such as NMI-352, for enhanced pharmacokinetics and tumor uptake. Targeting is achieved by incorporating folate ligands on the NE surface, which facilitate receptor-mediated endocytosis via the folate receptor α, commonly overexpressed in several cancers such as ovarian cancer. The mechanism of action is presumed to be similar to other platinum-based chemotherapeutics – DNA crosslinking and subsequent inhibition of DNA replication – but is specifically optimized for overcoming multidrug resistance and limiting toxicity through nanoemulsion delivery. Pharmacokinetic studies in animal models have demonstrated prolonged circulation time and stability of NEs loaded with difattyacid platins, while longer fatty acid chains (distearyplatin) correlate to reduced cytotoxic potency in vitro compared to related compounds[5][3].

Other names

distearyplatin